JKJeremy Liu Chen Kiow

Jeremy Liu Chen Kiow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeremy Liu Chen Kiow has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Mickael Bouin

    University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, Canada

    4 shared publications
  • Sacha Sidani

    Montreal University Hospital Research Center, Montreal, Quebec, Canada

    3 shared publications
  • Benoit Panzini

    University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, Canada

    2 shared publications
  • Brian Bressler

    Affiliations Department of Medicine, University of British Columbia, Vancouver, Canada, Division of Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, IBD Centre of BC, Vancouver, Canada

    2 shared publications
  • Roupen Djinbachian

    University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, Canada

    2 shared publications
  • Simon Bouchard

    University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, Canada

    2 shared publications

Latest Publications

  • Open Access

    A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing

    by Jeremy Liu Chen Kiow, Cristian Massaro, Efrain Cruz Jimenez, Itay Kalisky, Genelle Lunken, Yvette Leung, Brian Bressler, Greg Rosenfeld

    Despite substantial recent progress in inflammatory bowel disease (IBD) therapies, there remains a large proportion of patients who are non-responders or develop significant adverse events. Accurate data registries may assist clinicians and researchers to gain insights into IBD and provide opportunities to improve overall patient care. Most data registries are limited by the amount of time and resources needed to collect and record patient-level data. We describe and validate a novel IBD repository (IBD Data Lake), leveraging machine learning and natural language processing (NLP) techniques, as useful tools to curate and retrieve pertinent, real-time clinical data in the IBD population. Structured and unstructured data were extracted from patients’ electronic medical record and were transferred to a secure cloud infrastructure and curated into a searchable database. A customized user interface was created, and an advanced NLP service (Comprehend Medical) was employed to extract clinical information from unstructured data from medical documents. Chart review served as the gold standard for validation. Between July 1, 2018 and July 31, 2023, 208 (104 IBD and 104 matched non-IBD) patients were retrieved. The IBD Data Lake’s performance metrics for identifying IBD patients were as follows: sensitivity 98.1%, specificity 97.1%, and accuracy 97.6%. The machine learning/NLP components demonstrated high performance in analyzing key IBD characteristics: for distinction of ulcerative colitis or Crohn’s disease, sensitivity was 100% and specificity 98.2%; for smoking status, sensitivity was 100% and specificity 96.9%; and for extraintestinal manifestations, sensitivity was 92% and specificity 100%. A novel IBD Data Lake that integrates machine learning and NLP techniques has been established and validated. IBD patients were identified with high accuracy and the machine learning/NLP components enable comprehensive and timely data extraction. This will ultimately lay the groundwork for recruitment of specific IBD cohorts of interest to address the gaps that remain in our knowledge.

  • Computer-Aided Colonoscopy Alert Fatigue and Its Effect on Adenoma Detection

    by Felix Huang, Victoire Michal, Roupen Djinbachian, Megan Oleksiw, Douglas K. Rex, Robert Battat, Erik Deslandres, Mickael Bouin, Jeremy Liu Chen Kiow, Benoit Panzini, et al.

    INTRODUCTION: Computer-aided detection (CADe) can improve colonoscopy adenoma detection rates (ADR). However, prolonged exposure to repeated alerts may lead to alert fatigue, potentially diminishing its effectiveness. We sought to determine whether alert fatigue occurs during CADe use and, if so, how it influences ADR throughout the day. METHODS: We conducted a secondary analysis of a prospectively collected cohort to evaluate how ADR varied with and without CADe in a pragmatic, real-world implementation. Elective colonoscopies performed at the University of Montreal Hospital Center were analyzed according to their position within the endoscopist's daily schedule. The primary outcome was ADR across procedure order, adjusted for withdrawal time (WT). Secondary outcomes included adenomas per colonoscopy, ADR by time of day, and ADR across different WT categories. RESULTS: A total of 1,700 colonoscopies were analyzed, including 880 with CADe assistance and 820 without. In the CADe-unassisted group, ADR remained stable throughout the day (1st–3rd procedures: 39.4%, 95% confidence intervals (CI) [35.1–43.8]; 4th–7th procedures: 40.9%, 95% CI [32.9–49.5]). By contrast, ADR in CADe-assisted procedures was markedly higher in the first 3 procedures (49.9%, 95% CI [45.5–54.3]) but dropped significantly to 39.9% (95% CI [33.8–46.3]) in later procedures. This pattern was consistent when ADR was assessed by time of day. Similarly, adenomas per colonoscopy were significantly higher in early CADe-assisted procedures (mean increase +0.27, 95% CI [0.14–0.41], P < 0.001), but this benefit disappeared in later procedures (+0.11, 95% CI [–0.09 to 0.31], P = 0.51). WT analysis further supported this effect: ADR gains per additional minute were higher in unassisted colonoscopies (21.6% early vs 15.3% late) than in CADe-assisted colonoscopies (10.5% early vs 10.1% late). DISCUSSION: CADe assistance significantly improved ADR during early-day colonoscopies, but this benefit disappeared in later-day procedures. This pattern suggests that alert fatigue may limit endoscopists' responsiveness to CADe prompts as the day progresses.


  • Open Access

    Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

    by Jeremy Liu Chen Kiow, Thomas Hoang, Harjot K Bedi, Zhina Majdzadeh Ardekani, Daniel Rosenfeld, Marica Reise-Filteau, Brian Bressler, Yvette Leung, Greg Rosenfeld

    BACKGROUND Over the last decade, the treatment options for inflammatory bowel disease (IBD) have significantly progressed with the emergence of new medications designed to target various immune pathways and mitigate inflammation. Adalimumab (ADA) is a tumor necrosis factor alpha antagonist and stands as an effective treatment for IBD. In April 2021, the province of British Columbia implemented a mandatory non-medical switch policy of the ADA originator Humira® to ADA biosimilars. Biosimilars offer a potential cost-effective, safe, and efficacious alternative to the originator, yet there remains limited real-world evidence on long-term outcomes of ADA non-medical switching in IBD. AIM To assess the long-term outcomes of non-medical switching from the ADA originator Humira® to an ADA biosimilar among IBD patients. METHODS A retrospective observational chart review study was conducted on IBD patients eligible for the provincially mandated non-medical switch to an ADA biosimilar. The primary outcome was treatment persistence at 30 months post-switch. Secondary outcomes included the proportion of and reasons for therapy alteration or ADA discontinuation, loss of response (LOR) rates, adverse events (AE), and clinical and biochemical remission status. Patients who remained on the originator throughout the switch period, through compassionate support or private pay, constituted the comparison group. RESULTS Patients in the originator (n = 43) and biosimilar switch (n = 228) groups displayed similar demographics and baseline disease characteristics. By the study endpoint of 30 months, there was no difference in the rate of treatment persistence in either group (n = 36, 83.7% originator group vs n = 201, 88.2% biosimilar group, P = 0.451). Treatment persistence demonstrated similar rates of discontinuation between both study groups (log-rank P = 0.543). There was a numerical but not statistically significant difference in rates of adverse outcomes between either group (39.5% originator vs 28.9% biosimilars, P = 0.206). This included comparable rates of LOR (27.9% vs 17.5%) or AE (11.6% vs 11.4%) between the originator and biosimilar cohorts, respectively. C-reactive protein and fecal calprotectin levels were similar one year pre- and post-switch. CONCLUSION These data support the long-term efficacy and safety of non-medical ADA switching in IBD and will help inform patients and physicians in jurisdictions currently undergoing biosimilar switching.


  • Measuring Size of Colorectal Polyps Using a Virtual Scale Endoscope or Visual Assessment: A Randomized Controlled Trial

    by Mahsa Taghiakbari, Roupen Djinbachian, Claire Haumesser, Sacha Sidani, Jeremy Liu Chen Kiow, Benoit Panzini, Daniel von Renteln

    INTRODUCTION: This study aimed to compare the accuracy of polyp size measurements using a virtual scale endoscope (VSE) with an integrated laser-based adaptive scale function and visual assessment (VA) during colonoscopies. METHODS: We conducted a single-blinded, prospective randomized controlled trial. Eligible patients (aged 45–80 years) undergoing screening, surveillance, or diagnostic colonoscopies were randomly assigned (1:1) into 2 groups. In the intervention group, all detected polyps were measured for size using VSE; in the control group, all polyps were measured using VA. Size measurements were compared with a reference standard of digital caliper measurement immediately post polypectomy. The primary outcome was the relative accuracy of real-time VSE measurement compared with VA. Secondary outcomes included the mean differences and the correlations between VSE or VA sizes and the reference standard of measurement. RESULTS: Overall, 230 patients were enrolled and randomized. The relative size measurement accuracy of VSE was 84% in 118 polyps, which was significantly higher than that of VA (105 polyps; 68.4%, P < 0.001). VSE resulted in a significantly higher percentage of size measurements within 25% of true size compared with VA (81.4% vs 41%, P < 0.001). VSE had a significantly lower percentage for >5-mm polyps incorrectly sized as 1–5 mm compared with VA (13.5% vs 57.1%; P < 0.001) and a significantly lower percentage for >3-mm polyps incorrectly sized as 1–3 mm compared with VA (11.3% vs 56.5%; P < 0.001). DISCUSSION: VSE significantly improves the size measurement accuracy of colorectal polyps during colonoscopies compared with VA and results in fewer misclassifications at relevant decision-making size thresholds.


  • Tu1441: EVALUATING DRUG SUSTAINABILITY, EFFICACY AND SAFETY OF BIOLOGIC AGENTS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER RETROSPECTIVE STUDY

    by Petra A. Golovics, Jean-Frederic Leblanc, Gustavo Hahn, Panu Wetwittayakhlang, Abdulrahman Qatomah, Anna Wang, Levon Boodaghians, Jeremy Liu Chen Kiow, Maryam Al Ali, Gary Wild, et al.

  • CHRONIC ASA USE AND ITS EFFECT ON METAL STENT PATENCY IN MALIGNANT DISTAL BILIARY OBSTRUCTION: A LARGE INTERNATIONAL MULTICENTER COHORT STUDY

    by Kristina Candido, Simon Bouchard, Dora C. Huang, Christopher Hansen-Barkun, Avijit Chatterjee, Charles Menard, Gurpal S. Sandha, Fergal Donnellan, Jennifer Telford, Etienne Desilets, et al.

  • Lidocaine before esophageal manometry and ambulatory pH monitoring: A randomized controlled trial

    by George Wahba, Elissaveta Neshkova, Gabrielle Jutras, Jeremy Liu Chen Kiow, Marianne Clément, Philippe Willems, Benny‐Darold Eouani, Olivier Courbette, Éloïse Ayuso, Mickael Bouin

    Background: Lidocaine is commonly applied to improve the tolerance of esophageal manometry (EM) and ambulatory pH monitoring (PM). We recently published data suggesting a benefit to this practice and we aimed to confirm these findings in a randomized trial.Methods: We conducted a double‐blind, randomized trial of lidocaine nasal spray versus placebo (saline) before EM and PM. Patients referred to our center who met inclusion criteria were enrolled. Patients were asked to fill a questionnaire after their test and patient‐reported adverse effects were compared.Key Results: Three hundred and four patients were enrolled in our trial. Lidocaine and placebo groups were demographically similar. The primary outcome, pain during catheter insertion, occurred in 60/148 (40.5%) patients in the lidocaine group versus in 72/152 (47.4%) patients in the placebo group (OR: 0.76 [95% CI: 0.48–1.20]; p = 0.23). Patients receiving lidocaine were less likely to report nausea during test recording (OR: 0.48 [95% CI: 0.24–0.91]; p = 0.02) and reported slightly lower intensity of pain during both catheter insertion and test recording (4.68 ± 2.06 versus 5.41 ± 2.24 on 10; p = 0.048 and 3.71 ± 2.00 versus 4.93 ± 2.55 on 10; p = 0.03, respectively). Furthermore, patients receiving lidocaine were less likely to report their test as globally uncomfortable and painful (57% vs. 75%; p = 0.003 and 14% vs. 21%; p = 0.02, respectively). No events of systemic lidocaine toxicity occurred during the study period.Conclusions: Routine use of lidocaine before esophageal function tests does not reduce pain during catheter insertion but may provide other modest benefits with limited toxicity.


  • Open Access

    Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing

    by Jeremy Liu Chen Kiow, Ratiba Bellila, Amelie Therrien, Sacha Sidani, Mickael Bouin

    Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing


  • High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis

    by Jeremy Liu Chen Kiow, Catherine Vincent, Sacha Sidani, Mickael Bouin

    Background: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease affecting mainly middle‐aged women. An alteration in intestinal motility has been well documented in cirrhosis predisposing to small intestinal bacterial overgrowth (SIBO). Patients with PBC frequently complain of various gastrointestinal symptoms compatible with SIBO. No study has specifically been published to this day to determine the occurrence of SIBO in PBC. Our objective was to determine the prevalence of SIBO in patients with PBC.Methods: Retrospective study from 2010 to 2018. All patients diagnosed with PBC during this period had a systematic screening for SIBO in their diagnostic workup. The diagnosis of SIBO was made by a carbohydrate breath test (lactulose and/or glucose). Clinical and paraclinical factors of patients were compared with a control group of healthy subjects.Key Results: Ninety‐eight subjects were included in the study (mean age 49, range 21‐88 years) including 58 patients with PBC and 40 healthy subjects. The PBC group was older than the control group (mean age 56, range 31‐88 vs 39, range 21‐62 years; P < .001), but identical for gender and body mass index. The prevalence of SIBO was higher in PBC versus controls (32.8% vs 2.5%; P < .001). The PBC group with SIBO had significantly more diarrhea (78.9% vs 35.9%; P < .05) than the PBC group without SIBO, but the prevalence of abdominal pain and bloating was similar.Conclusions & Inferences: The high occurrence of SIBO in PBC may explain some of the frequently reported gastrointestinal symptoms. This study justifies the systematic screening for SIBO in PBC.